We use cookies to help provide you with the best possible online experience.
By using this site, you agree that we may store and access cookies on your device. Cookie policy.
Cookie settings.
Functional Cookies
Functional Cookies are enabled by default at all times so that we can save your preferences for cookie settings and ensure site works and delivers best experience.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
UK-EDI: UK Early Detection Initiative for Pancreatic Cancer
UK-EDI is a research programme funded by Cancer Research UK Bay Medical group (BMG) is supporting this study and is inviting people aged 50 years or older who have been diagnosed with Type 2 diabetes within the last six months.
Why are we doing this study
UK-EDI will explore the link between new-onset diabetes and pancreatic cancer with the aim of finding ways to diagnose pancreatic cancer earlier.
Blood samples and clinical information will be collected from participants at appointments every six months for two years. Appointments will be held at BMG York Bridge site and carried out by our Research Nurses - each visit will last about an hour.
What is involved in the study
- You will make 5 research visits to the clinic over 2 years. Expenses to cover travel to each clinic visit will be provided.
- You will be asked to provide information about your health.
- You will answer questionnaires about your health and diabetes.
- You will provide samples of your blood for research.
Who can take part?
- Patients aged 50 and over at the time of the study
- Patients with a new-onset type 2 diabetes diagnosed within 6 months of study entry.
We are looking for volunteers to take part in a study that will help identify who is at risk of developnig pancreatic cancer.
Most cases of Type 2 diabetes are due to lifestyle or genetic factors, but in approximately 1 in 100 individuals diagnosed with type 2 diabetes, the diagnosis is believed to be an early sign associated with the development of pancreatic cancer.
It is hoped that this research will eventually lead to improvements in detecting and diagnosing pancreatic cancer early.